vs

Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Oncology Institute, Inc. is the larger business by last-quarter revenue ($142.0M vs $93.1M, roughly 1.5× HIVE Digital Technologies Ltd.). Oncology Institute, Inc. runs the higher net margin — -5.3% vs -98.1%, a 92.8% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 41.6%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 22.5%).

Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

HIVE vs TOI — Head-to-Head

Bigger by revenue
TOI
TOI
1.5× larger
TOI
$142.0M
$93.1M
HIVE
Growing faster (revenue YoY)
HIVE
HIVE
+177.0% gap
HIVE
218.6%
41.6%
TOI
Higher net margin
TOI
TOI
92.8% more per $
TOI
-5.3%
-98.1%
HIVE
Faster 2-yr revenue CAGR
HIVE
HIVE
Annualised
HIVE
102.2%
22.5%
TOI

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
HIVE
HIVE
TOI
TOI
Revenue
$93.1M
$142.0M
Net Profit
$-91.3M
$-7.5M
Gross Margin
-27.1%
Operating Margin
-4.9%
Net Margin
-98.1%
-5.3%
Revenue YoY
218.6%
41.6%
Net Profit YoY
-234.0%
43.0%
EPS (diluted)
$-0.38
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIVE
HIVE
TOI
TOI
Q4 25
$93.1M
$142.0M
Q3 25
$87.3M
$136.6M
Q2 25
$45.6M
$119.8M
Q1 25
$104.4M
Q4 24
$29.2M
$100.3M
Q3 24
$22.6M
$99.9M
Q2 24
$32.2M
$98.6M
Q1 24
$94.7M
Net Profit
HIVE
HIVE
TOI
TOI
Q4 25
$-91.3M
$-7.5M
Q3 25
$-15.8M
$-16.5M
Q2 25
$35.0M
$-17.0M
Q1 25
$-19.6M
Q4 24
$68.2M
$-13.2M
Q3 24
$80.0K
$-16.1M
Q2 24
$-18.3M
$-15.5M
Q1 24
$-19.9M
Gross Margin
HIVE
HIVE
TOI
TOI
Q4 25
-27.1%
Q3 25
4.7%
Q2 25
-13.6%
Q1 25
Q4 24
-43.7%
Q3 24
-66.1%
Q2 24
-7.4%
Q1 24
Operating Margin
HIVE
HIVE
TOI
TOI
Q4 25
-4.9%
Q3 25
-5.9%
Q2 25
-9.4%
Q1 25
-9.5%
Q4 24
-11.9%
Q3 24
-13.9%
Q2 24
-16.6%
Q1 24
-19.0%
Net Margin
HIVE
HIVE
TOI
TOI
Q4 25
-98.1%
-5.3%
Q3 25
-18.1%
-12.1%
Q2 25
76.8%
-14.2%
Q1 25
-18.8%
Q4 24
233.2%
-13.1%
Q3 24
0.4%
-16.1%
Q2 24
-56.7%
-15.7%
Q1 24
-21.0%
EPS (diluted)
HIVE
HIVE
TOI
TOI
Q4 25
$-0.38
$-0.04
Q3 25
$-0.07
$-0.14
Q2 25
$0.18
$-0.15
Q1 25
$-0.21
Q4 24
$0.52
$-0.14
Q3 24
$0.00
$-0.18
Q2 24
$-0.17
$-0.17
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIVE
HIVE
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
Stockholders' EquityBook value
$559.3M
$-15.7M
Total Assets
$624.0M
$164.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIVE
HIVE
TOI
TOI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$40.5M
Q3 24
$31.7M
Q2 24
$9.9M
Q1 24
$29.8M
Stockholders' Equity
HIVE
HIVE
TOI
TOI
Q4 25
$559.3M
$-15.7M
Q3 25
$624.6M
$-12.3M
Q2 25
$560.5M
$-9.0M
Q1 25
$5.1M
Q4 24
$430.9M
$3.6M
Q3 24
$275.5M
$15.5M
Q2 24
$268.6M
$29.2M
Q1 24
$41.3M
Total Assets
HIVE
HIVE
TOI
TOI
Q4 25
$624.0M
$164.7M
Q3 25
$693.0M
$163.6M
Q2 25
$628.7M
$159.8M
Q1 25
$164.0M
Q4 24
$478.6M
$172.7M
Q3 24
$334.7M
$179.2M
Q2 24
$179.6M
Q1 24
$204.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIVE
HIVE
TOI
TOI
Operating Cash FlowLast quarter
$46.0M
$3.2M
Free Cash FlowOCF − Capex
$2.2M
FCF MarginFCF / Revenue
1.5%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIVE
HIVE
TOI
TOI
Q4 25
$46.0M
$3.2M
Q3 25
$-10.6M
$-12.6M
Q2 25
$10.2M
$-10.2M
Q1 25
$-5.0M
Q4 24
$-28.5M
$4.2M
Q3 24
$-2.2M
$819.0K
Q2 24
$-4.4M
$-15.7M
Q1 24
$-15.9M
Free Cash Flow
HIVE
HIVE
TOI
TOI
Q4 25
$2.2M
Q3 25
$-13.2M
Q2 25
$-11.4M
Q1 25
$-5.3M
Q4 24
$-55.5M
$2.4M
Q3 24
$-34.7M
$417.0K
Q2 24
$-17.5M
Q1 24
$-16.5M
FCF Margin
HIVE
HIVE
TOI
TOI
Q4 25
1.5%
Q3 25
-9.7%
Q2 25
-9.5%
Q1 25
-5.1%
Q4 24
-189.9%
2.4%
Q3 24
-153.4%
0.4%
Q2 24
-17.7%
Q1 24
-17.4%
Capex Intensity
HIVE
HIVE
TOI
TOI
Q4 25
0.7%
Q3 25
0.4%
Q2 25
1.0%
Q1 25
0.3%
Q4 24
92.5%
1.8%
Q3 24
143.9%
0.4%
Q2 24
1.9%
Q1 24
0.6%
Cash Conversion
HIVE
HIVE
TOI
TOI
Q4 25
Q3 25
Q2 25
0.29×
Q1 25
Q4 24
-0.42×
Q3 24
-26.94×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HIVE
HIVE

Segment breakdown not available.

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons